An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses

Oncolytic viruses offer an in situ vaccination approach to activate tumor-specific T cell responses. However, the upregulation of PD-L1 expression on tumor cells and immune cells leads to tumor resistance to oncolytic immunotherapy. In this study, we generate an engineered oncolytic virus that coexp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guan, Kang, Xi, Chen, Katherine S., Jehng, Tiffany, Jones, Lindsey, Chen, Jie, Huang, Xue F., Chen, Si-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070065/
https://www.ncbi.nlm.nih.gov/pubmed/32170083
http://dx.doi.org/10.1038/s41467-020-15229-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070065/
https://www.ncbi.nlm.nih.gov/pubmed/32170083
http://dx.doi.org/10.1038/s41467-020-15229-5

Ejemplares similares